Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
00399 INNOVATIVE PHAR
0.211
+0.009+4.46%
YOY
Do not show
Hide blank lines
(FY)2022/03/31(Q6)2021/09/30(FY)2021/03/31(Q6)2020/09/30
Assets
Current assets
Accounts receivable
-39.57% 9.26M 53.65% 19.78M -1.83% 15.32M -45.19% 12.87M
Advance deposits and other receivables
25.02% 5.61M 40.42% 5.06M 23.15% 4.49M -44.6% 3.6M
Cash and equivalents
-54.59% 4.08M -79.79% 2.41M -60.8% 8.99M -73.25% 11.93M
Total current assets
-34.2% 18.95M -4.07% 27.24M -31.73% 28.8M -61.91% 28.4M
Non-current assets
Intangible assets
0% 1.37B 0% 1.37B 0% 1.37B 0% 1.37B
Special items of non-current assets
137.94% 2.82M -98.28% 49K -65.45% 1.19M -- 2.84M
Total non-current assets
0.12% 1.38B -0.2% 1.37B -0.17% 1.37B -8.86% 1.38B
Total assets
-0.59% 1.39B -0.28% 1.4B -1.1% 1.4B -11.36% 1.4B
Liabilities
Current liabilities
Accounts payable
48.8% 8.15M 63.12% 8.38M -46.56% 5.48M -75.58% 5.14M
Amounts payable to associated parties-current liabilities
30.22% 85.76M 65.41% 75.86M 24.59% 65.86M 1071.44% 45.86M
Other payables and accrued expenses
135.77% 3.98M -57.33% 1.72M -67.2% 1.69M -92.97% 4.04M
Other loans-current liabilities
-- -- -- -- -- -- -- 7M
Financial lease liabilities-current liabilities
68.25% 1.88M -98.07% 41K -51.07% 1.12M -- 2.13M
Total current liabilities
-87.54% 99.77M -88.22% 86.01M 1035.06% 800.67M 785.67% 730.06M
Net current assets
89.53% -80.82M 91.63% -58.76M -2622.27% -771.87M -8824.71% -701.66M
Total assets less current liabilities
114.96% 1.3B 94.91% 1.31B -55.31% 602.54M -55.1% 674.4M
Non-current liabilities
Payments payable to related parties-non-current liabilities
-- -- 4.66% 16.49M -- -- 125.03% 15.75M
Financial lease liabilities-non-current liabilities
-- 968K -- -- -- -- -- 24K
Convertible notes and bonds
321.59% 871.79M 385.57% 797.1M -72.17% 206.78M -77.6% 164.16M
Special items of non-current liabilities
-26.58% 27.2M 0% 20.93M 2.02% 37.05M -67.41% 20.93M
Total non-current liabilities
269.09% 899.96M 315.46% 834.51M -68.76% 243.83M -75.47% 200.86M
Total liabilities
-4.29% 999.73M -1.12% 920.52M 22.72% 1.04B 3.27% 930.93M
Total assets less total liabilities
10.19% 395.27M 1.36% 480M -36.82% 358.71M -30.67% 473.54M
Total equity and non-current liabilities
114.96% 1.3B 94.91% 1.31B -55.31% 602.54M -55.1% 674.4M
Equity
Share capital
0% 14.64M 0% 14.64M 0% 14.64M 0% 14.64M
Reserve
7.54% -564.01M 2.76% -484.74M -50.61% -609.99M -148.49% -498.49M
Legal reserve
7.54% -564.01M 2.76% -484.74M -50.61% -609.99M -148.49% -498.49M
Shareholders' Equity
7.72% -549.37M 2.84% -470.1M -52.51% -595.35M -160.18% -483.85M
Non-controlling interest
-0.99% 944.63M -0.76% 950.09M -0.43% 954.06M 18.35% 957.39M
Total equity
10.19% 395.27M 1.36% 480M -36.82% 358.71M -30.67% 473.54M
Total equity and total liabilities
-0.59% 1.39B -0.28% 1.4B -1.1% 1.4B -11.36% 1.4B
Currency Unit
HKDHKDHKDHKD
Accounting Standards
HKASHKASHKASHKAS
Audit Opinions
Unqualified Opinion--Qualified opinion--
Auditor
Kaiyuan Xinde accounting firm co., Ltd.--Kaiyuan Xinde accounting firm co., Ltd.--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Pilot Pharmaceutical and Biotechnology Co., Ltd. is a Hong Kong investment holding company mainly engaged in pharmaceutical and biotechnology business. The company operates through five major divisions. The genetic testing Services Division provides genetic testing services in China and Hong Kong. Bio-industry products division distributes bio-industry products in China. Beauty equipment and products Trading Division is engaged in the trade of beauty equipment and products in Hong Kong, China. The securities investment division engages in securities investment in Hong Kong, China and outside Hong Kong, China. The R & D division is engaged in the R & D and commercialization of oral insulin products.
CEO: Nian Jiang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...